SGLT2 Inhibitors: The Sweet Success for Kidneys

被引：31

作者：

Dharia, Atit ^{[1
,2
]}

Khan, Abid ^{[1
,2
]}

Sridhar, Vikas S. ^{[1
,2
]}

Cherney, David Z., I ^{[1
,2
]}

机构：

[1] Univ Hlth Network, Dept Med, Div Nephrol, Toronto, ON, Canada

[2] Univ Toronto, Dept Med, Toronto, ON, Canada

来源：

ANNUAL REVIEW OF MEDICINE | 2023年 / 74卷

基金：

加拿大健康研究院;

关键词：

sodium glucose cotransporter 2 inhibitor; kidney outcomes; diabetic kidney disease; nondiabetic kidney disease; acute kidney injury; COTRANSPORTER; 2; INHIBITORS; GLUCOSE CO-TRANSPORTER-2 INHIBITORS; TYPE-2; DIABETES-MELLITUS; CARDIOVASCULAR OUTCOMES; DAPAGLIFLOZIN; DISEASE; EMPAGLIFLOZIN; PROTECTION; SAFETY; ERTUGLIFLOZIN;

D O I：

10.1146/annurev-med-042921-102135

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors) were originally developed as antidiabetic agents, with cardiovascular (CV) outcome trials demonstrating improved CV outcomes in patients with type 2 diabetes mellitus (T2D). Secondary analyses of CV outcome trials and later dedicated kidney outcome trials consistently reported improved kidney-related outcomes independent of T2D status and across a range of kidney function and albuminuria. Importantly, SGLT2 inhibitors are generally safe and well tolerated, with clinical trials and real-world analyses demonstrating a decrease in the risk of acute kidney injury. The kidney protective effects of SGLT2 inhibitors generally extend across different members of the class, possibly on the basis of hemodynamic, metabolic, anti-inflammatory, and antifibrotic mechanisms. In this review, we summarize the effects of SGLT2 inhibitors on kidney outcomes in diverse patient populations.

引用

页码：369 / 384

页数：16

共 99 条

[1] Sodium-glucose cotransporter 2 inhibition in non-diabetic kidney disease [J].

Almaimani, Mohanad ;

Sridhar, Vikas S. ;

Cherney, David Z. I. .

CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2021, 30 (05) :474-481

[2] Effect of Sodium-Glucose Cotransporter-2 Inhibitors on Endothelial Function: A Systematic Review of Preclinical Studies [J].

Alshnbari, Afnan S. ;

Millar, Sophie A. ;

O'Sullivan, Saoirse E. ;

Idris, Iskandar .

DIABETES THERAPY, 2020, 11 (09) :1947-1963

[3] Empagliflozin in Heart Failure with a Preserved Ejection Fraction [J].

Anker, Stefan D. ;

Butler, Javed ;

Filippatos, Gerasimos ;

Ferreira, Joao P. ;

Bocchi, Edimar ;

Boehm, Michael ;

Brunner-La Rocca, Hans-Peter ;

Choi, Dong-Ju ;

Chopra, Vijay ;

Chuquiure-Valenzuela, Eduardo ;

Giannetti, Nadia ;

Gomez-Mesa, Juan Esteban ;

Janssens, Stefan ;

Januzzi, James L. ;

Gonzalez-Juanatey, Jose R. ;

Merkely, Bela ;

Nicholls, Stephen J. ;

Perrone, Sergio V. ;

Pina, Ileana L. ;

Ponikowski, Piotr ;

Senni, Michele ;

Sim, David ;

Spinar, Jindrich ;

Squire, Iain ;

Taddei, Stefano ;

Tsutsui, Hiroyuki ;

Verma, Subodh ;

Vinereanu, Dragos ;

Zhang, Jian ;

Carson, Peter ;

Lam, Carolyn Su Ping ;

Marx, Nikolaus ;

Zeller, Cordula ;

Sattar, Naveed ;

Jamal, Waheed ;

Schnaidt, Sven ;

Schnee, Janet M. ;

Brueckmann, Martina ;

Pocock, Stuart J. ;

Zannad, Faiez ;

Packer, Milton .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (16) :1451-1461

[4] Summary of Recommendation Statements [J].

不详 .

KIDNEY INTERNATIONAL SUPPLEMENTS, 2012, 2 (01) :8-+

[5]

[Anonymous], 2008, Guidance for industry: diabetes mellitus-evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes

[6] SGLT2 Inhibition by Intraperitoneal Dapagliflozin Mitigates Peritoneal Fibrosis and Ultrafiltration Failure in a Mouse Model of Chronic Peritoneal Exposure to High-Glucose Dialysate [J].

Balzer, Michael S. ;

Rong, Song ;

Nordlohne, Johannes ;

Zemtsovski, Jan D. ;

Schmidt, Sonja ;

Stapel, Britta ;

Bartosova, Maria ;

von Vietinghoff, Sibylle ;

Haller, Hermann ;

Schmitt, Claus P. ;

Shushakova, Nelli .

BIOMOLECULES, 2020, 10 (11)

[7]

Bargman JM, 2001, J AM SOC NEPHROL, V12, P2158, DOI 10.1681/ASN.V12102158

[8] Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease [J].

Bhatt, Deepak L. ;

Szarek, Michael ;

Pitt, Bertram ;

Cannon, Christopher P. ;

Leiter, Lawrence A. ;

McGuire, Darren K. ;

Lewis, Julia B. ;

Riddle, Matthew C. ;

Inzucchi, Silvio E. ;

Kosiborod, Mikhail N. ;

Cherney, David Z. I. ;

Dwyer, Jamie P. ;

Scirica, Benjamin M. ;

Bailey, Clifford J. ;

Diaz, Rafael ;

Ray, Kausik K. ;

Udell, Jacob A. ;

Lopes, Renato D. ;

Lapuerta, Pablo ;

Steg, P. Gabriel .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (02) :129-139

[9] Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin [J].

Bolinder, Jan ;

Ljunggren, Osten ;

Kullberg, Joel ;

Johansson, Lars ;

Wilding, John ;

Langkilde, Anna Maria ;

Sugg, Jennifer ;

Parikh, Shamik .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2012, 97 (03) :1020-1031

[10] Sodium-glucose co-transporter-2 inhibitors and diabetic ketoacidosis: An updated review of the literature [J].

Bonora, Benedetta Maria ;

Avogaro, Angelo ;

Fadini, Gian Paolo .

DIABETES OBESITY & METABOLISM, 2018, 20 (01) :25-33

← 1 2 3 4 5 6 7 8 9 10 →